People · Operator
Named in public records as an officer, director or promoter · active 2011–2023 · Other Technology, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Calxeda, Inc. | — | Other Technology | Series C | $100.5M | $1.7B | 2011 |
| Slingshot Biosciences, Inc. | — | Biotech / Pharma | Series B | $49.1M | $334.7M | 2021 |
Jeffrey Kim at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeffrey Kim on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Sean Dalton | 1 | 7 |
| David Aronoff | 1 | 7 |
| Ken Lawler | 1 | 2 |
| Tom Lantzsch | 1 | 1 |
| Ross Goolsby | 1 | 1 |
| Daniel Durn | 1 | 1 |
| Nicolas J Barthelemy | 1 | 1 |
| Patrick J Weiss | 1 | 1 |
| Corey J Ritter | 1 | 1 |
| Andrew J Lee | 1 | 1 |
| Ronald J Silberman | 1 | 1 |
| Adam J Wieschhaus | 1 | 1 |
| Tom Lantzch | 1 | 1 |
| Howard Bubb | 1 | 1 |
| Barry Evans | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.